Quick Answer
Travere Therapeutics, Inc. reported Total Assets of $605.19 million for fiscal year 2025.
Travere Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $605.19M | +1.9% |
| 2024 | $594.12M | -24.7% |
| 2023 | $788.91M | +17.3% |
| 2022 | $672.59M | -13.4% |
| 2021 | $776.63M | +27.9% |
| 2020 | $607.44M | +0.4% |
| 2019 | $604.80M | -14.7% |
| 2018 | $709.16M | +36.3% |
| 2017 | $520.35M | -0.9% |
| 2016 | $525.28M | +2.5% |
| 2015 | $512.26M | +278.1% |
| 2014 | $135.47M | +560.9% |
| 2013 | $20.50M | +757.2% |
| 2012 | $2.39M | +12119.0% |
| 2011 | $19.6K | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $538.58M | +6.8% | -3.0% |
| June 30, 2025 | $555.31M | +0.8% | +1.2% |
| March 31, 2025 | $548.80M | -17.3% | -7.6% |
| December 31, 2024 | $594.12M | -24.7% | +17.8% |
| September 30, 2024 | $504.41M | -39.4% | -8.5% |
| June 30, 2024 | $551.12M | -25.2% | -16.9% |
| March 31, 2024 | $663.55M | -17.9% | -15.9% |
| December 31, 2023 | $788.91M | +17.3% | -5.3% |
- Travere Therapeutics, Inc. showed an increase of +1.9% in Total Assets compared to the prior fiscal year.
- Over the 2011–2025 period, Travere Therapeutics, Inc.’s total assets has grown by 3092342.5% (from $19.6 thousand to $605.19 million).
- The most recent figure is from Travere Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: